Retatrutide & Cagrilintide Pen (20mg/10mg)
£170.00
Storage Instructions
Store refrigerated at 2–8°C. Do not freeze. Protect from light.
Description
This research blend pen combines Retatrutide (20mg) and Cagrilintide (10mg). Retatrutide is a triple-agonist peptide targeting the GIP, GLP-1, and glucagon receptors simultaneously, while Cagrilintide is a long-acting acylated amylin analogue. The pre-filled pen provides a precision-dosed format for controlled laboratory dispensing in metabolic-signalling research.
Research Context
Preclinical research has examined Retatrutide's triagonist activity across GIP, GLP-1, and glucagon receptors and Cagrilintide's amylin-receptor signalling, including studies of their combined effects on metabolic pathways. Supplied exclusively for in vitro laboratory research purposes.
Related Products
This product is supplied for in-vitro laboratory research only. Not for human consumption, medical treatment, or cosmetic use.
Disclaimer for 31-32 Peptides Purchase
By purchasing from 31-32 Peptides, you acknowledge and agree that:
- Research Use Only: All products are exclusively sold for research purposes. They are not intended for human use, therapeutic, diagnostic, or clinical application.
- Not Medical Products: None of the products listed on our website are medical products, nor should they be marketed or used as such.
- Compliance and Responsibility: The buyer is responsible for ensuring compliance with all relevant laws and regulations. 31-32 Peptides holds no liability for misuse of products or any adverse outcomes.
Your purchase signifies your understanding and agreement to these terms.